<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Xencor</title>
	<atom:link href="http://www.xencor.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xencor.com</link>
	<description>Proteins By Design</description>
	<lastBuildDate>Tue, 21 Feb 2012 16:54:01 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.5</generator>
		<item>
		<title>Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies</title>
		<link>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/</link>
		<comments>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/#comments</comments>
		<pubDate>Tue, 21 Feb 2012 16:54:01 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PRESS RELEASES]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1852</guid>
		<description><![CDATA[Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life MONROVIA, Calif., USA and INGELHEIM, Germany – February 21, 2012 – Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and &#8230; <a href="http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/">&#8230;</a>]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/02/boehringer-ingelheim-and-xencor-enter-a-collaboration-agreement-for-the-development-manufacture-and-supply-of-biosuperior-monoclonal-antibodies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA (2011)</title>
		<link>http://www.xencor.com/2012/02/moore-gl-bautista-c-pong-e-nguyen-dh-jacinto-j-eivazi-a-muchhal-us-karki-s-chu-sy-lazar-ga-2011/</link>
		<comments>http://www.xencor.com/2012/02/moore-gl-bautista-c-pong-e-nguyen-dh-jacinto-j-eivazi-a-muchhal-us-karki-s-chu-sy-lazar-ga-2011/#comments</comments>
		<pubDate>Wed, 08 Feb 2012 19:49:04 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PUBLICATIONS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1842</guid>
		<description><![CDATA[A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs. Nov 1;3(6). [Epub ahead of print].]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/02/moore-gl-bautista-c-pong-e-nguyen-dh-jacinto-j-eivazi-a-muchhal-us-karki-s-chu-sy-lazar-ga-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US (2012)</title>
		<link>http://www.xencor.com/2012/01/tai-yt-horton-hm-kong-sy-pong-e-chen-h-cemerski-s-bernett-mj-nguyen-dh-karki-s-chu-sy-lazar-ga-munshi-nc-desjarlais-jr-anderson-kc-muchhal-us-2012/</link>
		<comments>http://www.xencor.com/2012/01/tai-yt-horton-hm-kong-sy-pong-e-chen-h-cemerski-s-bernett-mj-nguyen-dh-karki-s-chu-sy-lazar-ga-munshi-nc-desjarlais-jr-anderson-kc-muchhal-us-2012/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 20:39:27 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PUBLICATIONS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1838</guid>
		<description><![CDATA[Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Jan 13. [Epub ahead of print]]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/01/tai-yt-horton-hm-kong-sy-pong-e-chen-h-cemerski-s-bernett-mj-nguyen-dh-karki-s-chu-sy-lazar-ga-munshi-nc-desjarlais-jr-anderson-kc-muchhal-us-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Chu SY, Horton H, Pong E, Leung I, Chen H, Nguyen D-H, Bautista C, Muchhal US, Bernett M, Moore GL, Szymkowski DE, Desjarlais JR (2012)</title>
		<link>http://www.xencor.com/2012/01/chu-sy-horton-h-pong-e-leung-i-chen-h-nguyen-d-h-bautista-c-muchhal-us-bernett-m-moore-gl-szymkowski-de-desjarlais-jr-2012/</link>
		<comments>http://www.xencor.com/2012/01/chu-sy-horton-h-pong-e-leung-i-chen-h-nguyen-d-h-bautista-c-muchhal-us-bernett-m-moore-gl-szymkowski-de-desjarlais-jr-2012/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 20:21:17 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PUBLICATIONS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1832</guid>
		<description><![CDATA[Reduction of Total IgE by Targeted Coengagement of IgE B cell Receptor and FcgRIIb with Fc-Engineered Antibody. J Allergy Clin Immunol, doi:10.1016/j.jaci.2011.11.029]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/01/chu-sy-horton-h-pong-e-leung-i-chen-h-nguyen-d-h-bautista-c-muchhal-us-bernett-m-moore-gl-szymkowski-de-desjarlais-jr-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cemerski S, Chu SY, Moore GL, Muchhal US, Desjarlais JR, Szymkowski DE (2012)</title>
		<link>http://www.xencor.com/2012/01/cemerski-s-chu-sy-moore-gl-muchhal-us-desjarlais-jr-szymkowski-de-2012/</link>
		<comments>http://www.xencor.com/2012/01/cemerski-s-chu-sy-moore-gl-muchhal-us-desjarlais-jr-szymkowski-de-2012/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 20:18:33 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[PUBLICATIONS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1829</guid>
		<description><![CDATA[Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcgRIIb. Immunol Lett, in press.]]></description>
		<wfw:commentRss>http://www.xencor.com/2012/01/cemerski-s-chu-sy-moore-gl-muchhal-us-desjarlais-jr-szymkowski-de-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>03.19.12 – 03.22.12</title>
		<link>http://www.xencor.com/2011/12/03-19-12-%e2%80%93-03-22-12/</link>
		<comments>http://www.xencor.com/2011/12/03-19-12-%e2%80%93-03-22-12/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 21:38:04 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1818</guid>
		<description><![CDATA[IBC’s 3rd Biotherapeutics Analytical Summit (David Szymkowski, Ph.D., presenting; Baltimore, MD)]]></description>
		<wfw:commentRss>http://www.xencor.com/2011/12/03-19-12-%e2%80%93-03-22-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>03.25.12 &#8211; 03.30.12</title>
		<link>http://www.xencor.com/2011/10/03-25-12-03-30-12/</link>
		<comments>http://www.xencor.com/2011/10/03-25-12-03-30-12/#comments</comments>
		<pubDate>Tue, 25 Oct 2011 23:07:36 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1778</guid>
		<description><![CDATA[Gordon Research Conference &#8211; Antibody Biology &#038; Engineering (John Desjarlais, Ph.D., presenting; Galveston, TX)]]></description>
		<wfw:commentRss>http://www.xencor.com/2011/10/03-25-12-03-30-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>01.30.12 &#8211; 01.31.12</title>
		<link>http://www.xencor.com/2011/10/01-30-12-01-31-12-2/</link>
		<comments>http://www.xencor.com/2011/10/01-30-12-01-31-12-2/#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:35:40 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1736</guid>
		<description><![CDATA[4th Immunotherapeutics and Immunomonitoring Conference (John Desjarlais, Ph.D., presenting; San Diego, CA)]]></description>
		<wfw:commentRss>http://www.xencor.com/2011/10/01-30-12-01-31-12-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>02.29.12 &#8211; 03.02.12</title>
		<link>http://www.xencor.com/2011/10/02-29-12-03-02-12/</link>
		<comments>http://www.xencor.com/2011/10/02-29-12-03-02-12/#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:33:43 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1751</guid>
		<description><![CDATA[Biobetters &#038; Biosimilars – Technologies &#038; Development Strategies (Bassil Dahiyat, Ph.D., presenting; San Diego, CA)]]></description>
		<wfw:commentRss>http://www.xencor.com/2011/10/02-29-12-03-02-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>01.11.12 &#8211; 01.12.12</title>
		<link>http://www.xencor.com/2011/10/01-11-12-01-12-12/</link>
		<comments>http://www.xencor.com/2011/10/01-11-12-01-12-12/#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:32:29 +0000</pubDate>
		<dc:creator>xencor</dc:creator>
				<category><![CDATA[EVENTS]]></category>

		<guid isPermaLink="false">http://www.xencor.com/?p=1754</guid>
		<description><![CDATA[Antibodies for the 21st Century (John Desjarlais, Ph.D., presenting; San Diego, CA)]]></description>
		<wfw:commentRss>http://www.xencor.com/2011/10/01-11-12-01-12-12/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

